USNA

EX-99.1

2 q12026earningsreleaseex991.htm

EX-99.1

Document

USANA Health Sciences Reports First Quarter 2026 Results

Company Continues to Make Significant Progress on Transformation to Becoming a Leading Omnichannel Health and Wellness Platform

SALT LAKE CITY, May 5, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 4, 2026.

Key Financial Results

First Quarter 2026 vs. First Quarter 2025

•Net sales of $250 million versus $250 million.

•Net earnings of $7.5 million versus $9.4 million.

•Diluted EPS of $0.41 as compared with $0.49.

•Adjusted diluted EPS(1) of $0.61 as compared with $0.73.

•Adjusted EBITDA(2) of $28.4 million versus $29.8 million.

•Core Nutritional Active Customers of 404,000 versus 459,000.

•Hiya Active Monthly Subscribers of 186,000 versus 224,000.

•Company reiterates fiscal 2026 guidance.

Q1 2026 Consolidated Performance

Q1 2026

Year-Over-YearSequentially

Net Sales $250 million

Flat (+$8 million or +3% FX impact)

+11%

Net Earnings

$7.5 million

-20%

N/A

Diluted EPS $0.41

-16% N/A

Adjusted Diluted EPS(1)

$0.61

-16%

+2%

Adjusted EBITDA(2)

$28.4 million

-5%

+4%

Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.

“Our first quarter 2026 results reflect USANA’s continued evolution from a single-channel direct sales business to a diversified, omnichannel health and wellness enterprise," said Kevin Guest, Chairman and Chief Executive Officer. "Our omnichannel platform is intended to provide multiple growth engines, and early progress across our three segments reinforces confidence that our strategy will deliver sustained incremental value over time. The Core Nutritional business delivered solid sequential improvement during the quarter, driven by growth in total active customers in China in addition to continued focus on accelerating our new product launch initiatives. Meanwhile, Hiya established the operational foundation for a meaningfully stronger second half of the year and Rise Wellness generated triple-digit growth as Protein Pop hit Costco shelves nationwide.

“As we look ahead, the investments we are making today in product innovation, brand building, channel expansion, and technology modernization reinforce confidence in our strategic direction. These investments position us to compete effectively across the full spectrum of health-conscious consumer shopping preferences. We are committed to advancing our omnichannel strategy with urgency and discipline."

Q1 2026 Segment Results

Core Nutritional

Core Nutritional

Q1 2026

Year-Over-YearSequentially

Net Sales $204 million

-3%

+7%

Active Customers 404,000

-12%

+4%

Asia Pacific Region

Q1 2026

Year-Over-YearYear-Over-Year (Constant Currency)Sequentially

Net Sales $169 million

-2%

-6%

+12%

Active Customers 326,000

-13% N/A +7%

Asia Pacific Sub-Regions

Q1 2026

Year-Over-YearYear-Over-Year (Constant Currency)Sequentially

Greater ChinaNet Sales $123 million

+4%

Flat

+23%

Active 235,000

-7% N/A +13%

Customers

North AsiaNet Sales $15 million

-19%

-18%

-9%

Active 32,000

-29% N/A -9%

Customers

Southeast Asia PacificNet Sales $31 million

-14%

-20%

-10%

Active 59,000

-21% N/A -6%

Customers

Americas and Europe Region

Q1 2026

Year-Over-YearYear-Over-Year (Constant Currency)Sequentially

Net Sales

$35 million

-6%

-10%

-13%

Active Customers 78,000

-8% N/A -4%

Hiya Health

Q1 2026Year-Over-YearSequentially

Net Sales $32 million

-13%

+7%

Active Monthly Subscribers 186,000

-17%

+2%

Rise Wellness

Q1 2026

Year-Over-YearSequentially

Net Sales $14 million

+741%

+143%

Balance Sheet

The Company ended the quarter with $163 million in cash and cash equivalents and $14 million of debt. As of April 4, 2026, inventory totaled $99 million, a decrease of approximately $8 million, or -7% compared to balances at year-end 2025. This decrease

was driven by strong performance by Rise Wellness, particularly from the fulfillment of orders with key retailers.

The Company did not repurchase any shares during the quarter and has approximately $34 million remaining under the current share repurchase authorization as of the end of the first quarter.

Fiscal Year 2026 Outlook

The Company is reiterating its outlook for fiscal year 2026, as follows:

Fiscal Year 2026 Outlook

Range

Core Nutritional business net sales $720 to $765 million*

Hiya net sales$140 to $155 million

Rise Wellness net sales$65 to $80 million

Consolidated net sales$925 million to $1.0 billion

Net earnings

$20 million to $27 million

Diluted EPS $1.11 to $1.45

Adjusted diluted EPS(1)

$1.95 to $2.29

Adjusted EBITDA(2)

$101 million to $109 million

*Reflects an expected favorable currency exchange rate impact of approximately $19 million, or 3% on net sales and one less week of operations compared to fiscal year 2025 which was a 53-week year.

usna-20260217FALSE000089626400008962642026-02-172026-02-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 17, 2026

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation)

001-3502487-0500306 (Commission File No.)(IRS Employer Identification No.)

3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Address of principal executive offices, Zip Code) Registrant's telephone number, including area code: (801) 954-7100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 par value per shareUSNANew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition. On February 17, 2026, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended January 3, 2026. The release also announced that the Company will post a document titled “Management Commentary” on the Company’s website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company’s management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. These documents will be posted on the Company’s corporate website, www.usana.com.

The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 7.01    Regulation FD Disclosure The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits. (d)Exhibits

Exhibit No.Description 99.1Press release issued by USANA Health Sciences, Inc. dated February 17, 2026 (furnished herewith).

99.2Management Commentary provided by USANA Health Sciences, Inc. dated February 17, 2026 (furnished herewith).

104Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By:/s/ G. Douglas Hekking G. Douglas Hekking, Chief Financial Officer

Date: February 17, 2026

usna-20260112FALSE000089626400008962642026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 12, 2026

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation)

001-3502487-0500306 (Commission File No.)(IRS Employer Identification No.)

3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Address of principal executive offices, Zip Code) Registrant's telephone number, including area code: (801) 954-7100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 par value per shareUSNANew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition. On January 12, 2026, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing preliminary net sales for the full fiscal year ended January 3, 2026, and net sales guidance with respect to the Company's currently expected financial results for the fiscal year ending January 2, 2027. A copy of this press release is attached hereto as Exhibit 99.1

The information, including Exhibit 99.1, in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available

Item 7.01    Regulation FD Disclosure On January 12, 2026, the Company issued a press release announcing preliminary net sales for the fiscal year ended January 3, 2026 along with initial net sales guidance for fiscal year 2026. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01    Financial Statements and Exhibits. (d)Exhibits

Exhibit No.Description 99.1Press release issued by USANA Health Sciences, Inc. dated January 12, 2026 (furnished herewith).

104Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By:/s/ G. Douglas Hekking G. Douglas Hekking, Chief Financial Officer

Date: January 12, 2026